| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SSX4 |
| Uniprot No | O60224 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-188aa |
| 氨基酸序列 | MNGDDAFARRPRDDAQISEKLRKAFDDIAKYFSKKEWEKMKSSEKIVYVYMKLNYEVMTKLGFKVTLPPFMRSKRAADFHGNDFGNDRNHRNQVERPQMTFGSLQRIFPKIMPKKPAEEENGLKEVPEASGPQNDGKQLCPPGNPSTLEKINKTSGPKRGKHAWTHRLRERKQLVVYEEISDPEEDDE |
| 预测分子量 | 25.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SSX4重组蛋白的模拟参考文献示例(注：内容为虚构，仅用于格式参考)：
1. **标题**: "Recombinant SSX4 Protein Expression and Its Immunogenicity in Melanoma Patients"
**作者**: Smith J, et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了SSX4重组蛋白，发现其在黑色素瘤患者血清中能引发特异性抗体反应，提示其作为肿瘤疫苗候选抗原的潜力。
2. **标题**: "Structural Analysis of SSX4 Protein and Its Interaction with HDAC Complexes"
**作者**: Chen L, et al.
**摘要**: 通过X射线晶体学解析SSX4重组蛋白的三维结构，揭示了其C端结构域与组蛋白去乙酰化酶(HDAC)的结合机制，为靶向SSX4的癌症治疗提供依据。
3. **标题**: "SSX4 Recombinant Protein Induces T-cell Responses in Synovial Sarcoma"
**作者**: Müller R, et al.
**摘要**: 利用哺乳动物细胞系表达SSX4重组蛋白，体外实验证实其可激活患者来源的细胞毒性T细胞，支持SSX4在滑膜肉瘤免疫治疗中的应用价值。
4. **标题**: "Optimization of SSX4 Recombinant Production for Diagnostic Assay Development"
**作者**: Tanaka K, et al.
**摘要**: 通过优化真核表达系统提高SSX4重组蛋白产量，并验证其在ELISA检测中的稳定性，为癌症血清学诊断提供标准化工具。
(注：以上文献为示例性质，实际研究中请通过学术数据库检索真实发表论文。)
**Background of SSX4 Recombinant Protein**
The SSX4 (Synovial Sarcoma X breakpoint 4) protein belongs to the SSX family of cancer-testis (CT) antigens, which are predominantly expressed in germline cells but re-emerge in various malignancies. These antigens, including SSX1-4. are characterized by their restricted expression in normal tissues (primarily the testis) and aberrant activation in cancers, making them attractive targets for immunotherapy. SSX4. encoded by the *SSX4* gene located on chromosome X, shares structural homology with other SSX members, featuring a conserved N-terminal domain involved in transcriptional repression and a C-terminal divergent region implicated in protein-protein interactions.
SSX4’s biological role remains partially understood, though it is hypothesized to participate in chromatin remodeling and transcriptional regulation. Its dysregulation in cancers—such as melanoma, breast cancer, and synovial sarcoma—correlates with tumor progression and immune evasion. Recombinant SSX4 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active forms for research. This involves cloning the *SSX4* gene into expression vectors, followed by protein purification via affinity chromatography (e.g., His-tag systems).
Recombinant SSX4 serves as a critical tool for studying its immunogenicity, structure-function relationships, and interactions with immune cells. It is also explored in diagnostic applications (e.g., antibody validation) and therapeutic development, including cancer vaccines or T-cell-based therapies targeting SSX4-expressing tumors. Despite challenges like low endogenous expression and antigen variability, SSX4’s tumor-specificity positions it as a promising candidate for precision oncology. Ongoing research aims to elucidate its mechanistic contributions to oncogenesis and optimize its use in clinical settings.
×
